BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.

Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

MyoKardia

Eidos Therapeutics

Blue Owl

CPP Investments

Qatar Investment Authority

Perceptive Advisors

Janus Fund

Viking Global Investors

Cormorant Capital

Kohlberg Kravis Roberts

Hercules Capital

AIG Investments

Sequoia Capital

Aisling Capital

BridgeBio

Our chief medical officer at BridgeBio Gene Therapy, 👤 Adam Shaywitz, M.D., Ph.D., will chair a panel today at the PMWC - Precision Medicine World Conference on novel clinical design approaches in rare diseases. Learn more about his session here: https://bit.ly/3vwZsdq

This week Dunni Odumosu, MS, vice president of regulatory affairs at BridgeBio Gene Therapy will lead a workshop at the Gene Therapy Regulatory Affairs Summit on the key learnings and best practices for optimizing regulatory interactions in the rapidly evolving field of gene therapy. Check out the agenda: https://bit.ly/3TWKJTs

In our latest episode of #OnRare we were privileged to speak with Effie Parks, a rare mom, a patient advocate, a podcaster, and host of “Once Upon a Gene.” Effie candidly shares her experience of being a new mom to a child living with a rare condition and her journey into the advocacy space. https://bit.ly/47H0S2q

We appreciate the partnership with the limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) advocacy groups and applaud their many achievements. We are excited to continue working on behalf of the LGMD community and to see what is next for 2024. Together We Are Stronger!

We are proud to share that the positive results from our Phase 3 ATTRibute-CM study have been published in the NEJM Group. We submitted our New Drug Application for acoramidis to the U.S. FDA in 2023 and intend to submit additional marketing authorization applications to regulatory bodies this year. Learn more: https://bit.ly/3TPN8iF

Thank you JPMorgan Chase & Co. for inviting us to present at the Annual Healthcare Conference! Our CEO and founder, Neil Kumar, Ph.D. shared our learnings across the ATTR-CM space since last year as well as provided updates on our late-stage programs, our research & early development candidates, and our priorities for 2024. #JPM24 Listen to our presentation here: https://bit.ly/3H3uL2b

To wrap up our 2023, our On Rare team recalled the wonderful, rare conversations we held with our extraordinary guests. Join us for a look back at 2023 and don’t forget to subscribe to learn more from our guests in 2024. https://bit.ly/3tL5rLd

BridgeBio founder & CEO Neil Kumar, Ph.D. is presenting at the J.P. Morgan 42nd Annual Healthcare Conference today at 8:15 a.m. PT. Join and learn about our goal to develop medicines for people with genetic diseases and cancers. Listen to the presentation here: https://bit.ly/3H3uL2b

We are on a mission to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases and cancers. Learn more about our upcoming presentation at the J.P. Morgan Annual Healthcare Conference, where we will discuss our milestones for the year. Read more: https://bit.ly/3H6969k

The U.S. FDA has cleared our investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRASG12C. We intend to begin enrollment of patients with KRASG12C mutant non-small cell lung cancer into our ONKORAS-101 trial, which is expected to begin in the first half of this year. Learn more: https://bit.ly/3H5JyJB

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			40.56M -	8.25M 79.66%	69.72M 745.14%	77.65M 11.38%	9.30M 88.02%
cost of revenue			2.50M -		3.11M -	3.43M 10.28%	2.45M 28.77%
gross profit			38.06M -	8.25M 78.33%	66.60M 707.39%	74.21M 11.43%	6.86M 90.76%
selling and marketing expenses
general and administrative expenses	13.30M -	43.59M 227.67%	94.35M 116.47%	145.68M 54.40%
selling general and administrative expenses	13.30M -	43.59M 227.67%	94.35M 116.47%	145.68M 54.40%	192.21M 31.94%	143.19M 25.50%	150.59M 5.17%
research and development expenses	30.56M -	140.07M 358.41%	209.95M 49.88%	337.05M 60.54%	454.14M 34.74%	402.90M 11.28%	455.71M 13.11%
other expenses		-1.29M -	-1.21M 6.27%	1.63M 235.04%	35.82M 2,092.35%	100.45M 180.40%	270K 99.73%
cost and expenses	43.86M -	183.66M 318.76%	306.80M 67.05%	482.73M 57.34%	646.35M 33.89%	546.09M 15.51%	608.75M 11.47%
operating expenses	43.86M -	183.66M 318.76%	304.30M 65.69%	482.73M 58.64%	646.35M 33.89%	546.09M 15.51%	606.30M 11.03%
interest expense	13K -	2.55M 19,492.31%	8.77M 244.13%	36.66M 318.20%	46.78M 27.62%	80.44M 71.96%	81.29M 1.06%
ebitda	-43.82M -	-182.98M 317.57%	-279.40M 52.70%	-468.83M 67.80%	-539.68M 15.11%	-353.68M 34.46%	-574.64M 62.48%
operating income	-43.86M -	-183.66M 318.76%	-266.24M 44.96%	-474.48M 78.22%	-579.75M 22.19%	-471.87M 18.61%	-607.37M 28.72%
depreciation and amortization	260K -	245K 5.77%	-13.16M 5,473.06%	5.65M 142.91%	40.07M 609.33%	118.19M 194.97%	6.49M 94.51%
total other income expenses net	26K -	14.75M 56,638.46%	-22.34M 251.47%	-31.01M 38.76%	-6.71M 78.37%	-12.78M 90.53%	9.44M 173.89%
income before tax	-43.83M -	-169.45M 286.59%	-288.58M 70.31%	-505.49M 75.16%	-586.45M 16.02%	-484.65M 17.36%	-653.25M 34.79%
income tax expense	-13.49M -	16.76M 224.23%	-28.15M 267.99%	-21.56M 23.39%	52.84M 345.06%	9.31M 82.38%	71.51M 667.93%
net income	-30.57M -	-130.75M 327.77%	-260.44M 99.19%	-483.93M 85.81%	-639.30M 32.11%	-493.96M 22.73%	-643.20M 30.21%
weighted average shs out	92.33M -	92.33M 0%	105.10M 13.83%	118.00M 12.27%	144.36M 22.34%	147.47M 2.16%	162.79B 110,287.28%
weighted average shs out dil	92.33M -	92.33M 0%	105.10M 13.83%	118.00M 12.27%	144.36M 22.34%	147.47M 2.16%	162.79B 110,287.28%
eps	-0.33 -	-1.42 330.30%	-2.48 74.65%	-4.10 65.32%	-4.43 8.05%	-3.35 24.38%	-0.00 99.88%
epsdiluted	-0.33 -	-1.42 330.30%	-2.48 74.65%	-4.10 65.32%	-4.43 8.05%	-3.35 24.38%	-0.00 99.88%

COM:BRIDGEBIO

BridgeBio Pharma, Inc.

Last Close

23.24

22/11 21:00

Market Cap

4.97B

Beta: -

Volume Today

2.05M

Avg: -

Preview